Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis Benign”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Testing effectiveness (Phase 2)Looking for participantsNCT05359653
What this trial is testing

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Who this might be right for
Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary Progressive+4 more
University of California, San Francisco 74
Not applicableUnknownNCT04578262
What this trial is testing

Epley Manoeuvre in Participants With Multiple Sclerosis Diagnosed From Benign Paroxysmal Positional Vertigo

Who this might be right for
Benign Paroxysmal Positional VertigoMultiple Sclerosis
University of Seville 80
Not applicableLooking for participantsNCT06065852
What this trial is testing

National Registry of Rare Kidney Diseases

Who this might be right for
Adenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more
UK Kidney Association 35,000
Large-scale testing (Phase 3)Study completedNCT00790400
What this trial is testing

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Who this might be right for
Tuberous Sclerosis Complex (TSC)Lymphangioleiomyomatosis (LAM)
Novartis Pharmaceuticals 118
Testing effectiveness (Phase 2)Study completedNCT06322342
What this trial is testing

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Who this might be right for
Central Nervous System (CNS) LesionsBrain MetastasesBrain Neoplasms+22 more
Reveal Pharmaceuticals Inc. 18